Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI


Primary Symbol: V.BTI.H Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by jdstoxon Sep 24, 2018 3:11pm
143 Views
Post# 28679677

RE:RE:Deals, deals and more deals

RE:RE:Deals, deals and more dealsFair enough, regardless.

So far, xB3 has shown itself to be a top level candidate, if not the top level candidate, to be the key that gets drugs into the CNS.

Bioasis has embarked on the studies and other activities to prove that, one way or the other.

If that key, xB3, does only one thing, effectively and safely treats tumours in the brain in a manner similar to how they can be treated in the body, then that's one heeluva swell situation for shareholders to be in. Treating neuro diseases is a wide open unmet field that's worth tens of billions per year.

So if we've got the key, then it's got to be worth something, probably a lot.

I can't think of any other reason for shareholders to own this stock, or for the Bioasis team to come on board to prove that, other than that the potential value makes it all worth it.

I can't engage in public speculation, or give guidance to anybody. The company has stated that there will be no public discussion of BD deals unless and until they happen. But it seems to me and to most everybody else that whoever comes up with such a key to the brain should be a big winner. That's just following the general principles of business.

If you build it, they will come. 

Almost silly to think that they wouldn't.

jdstox

Bullboard Posts